Drug-drug interaction (DDI) assessments of ruxolitinib, a...

  • Main
  • 2019 / 05
  • Drug-drug interaction (DDI) assessments of ruxolitinib, a...

Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions

Umehara, Kenichi, Huth, Felix, Jin, Yi, Schiller, Hilmar, Aslanis, Vassilios, Heimbach, Tycho, He, Handan
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
Drug Metabolism and Personalized Therapy
DOI:
10.1515/dmpt-2018-0042
Date:
May, 2019
File:
PDF, 758 KB
english, 2019
Conversion to is in progress
Conversion to is failed